Expert Testimony Highlights Pharmacist Training Gaps in Albertsons Opioid Trial
Trial testimony revealed training gaps in pharmacists' ability to spot opioid misuse in Albertsons case.
Why it matters: Pharmacists play a key role in preventing opioid diversion. This case could affect pharmacy compliance oversight and legal strategies in opioid litigation nationwide, relevant to legal and healthcare professionals managing regulatory risks.
- Albertsons dispensed over 641 million opioid pills in Washington between 2006 and 2022.
- More than 6.5 million prescriptions at Albertsons showed signs of potential misuse or diversion.
- Albertsons’ national pharmacy compliance team had only six employees from 2015 to 2020.
- Albertsons agreed to a $774 million opioid settlement in April 2026 covering state, local, and tribal claims.
In the current trial against Albertsons in Washington state, expert testimony has highlighted significant gaps in pharmacist training for identifying and managing warning signs—known as red flags—of opioid misuse or diversion. Pharmacists are expected to exercise professional judgment when dispensing opioids, but evidence presented questioned the adequacy of their preparation for this role.
According to trial records from Washington State Standard, Albertsons dispensed more than 641 million opioid pills in the state from 2006 to 2022. Of these, over 6.5 million prescriptions exhibited indicators of possible diversion or misuse.
Kelsey Endres of the Washington State Attorney General’s Office stressed pharmacies are the "last line of defense" against opioids entering illegal markets. This underscores pharmacists’ critical role in public health and regulatory compliance.
Marlee O’Neill, Executive Director of the Washington State Pharmacy Quality Assurance Commission, highlighted that while pharmacists apply education and judgment, sufficient and ongoing training is essential to correctly identify misuse risks.
Albertsons’ defense argued it provided guidance and monitoring for pharmacists’ decisions. However, as reported by Law360, the company maintained a pharmacy compliance staff of only six people nationwide from 2015 through 2020, raising questions about oversight capacity.
The trial also referenced prior incidents illustrating regulatory consequences, such as a 2017 Safeway pharmacy suspension due to delayed reporting of missing hydrocodone tablets to the DEA (U.S. Department of Justice announcement). This example signals enforcement risks faced by pharmacy chains regarding controlled substance reporting.
Albertsons settled nationwide opioid litigation for $774 million in April 2026, but this Washington trial continues to investigate specific compliance practices and their impact on public health outcomes.
The legal and healthcare communities will watch closely as the case may lead to new standards for pharmacy compliance, training, and regulatory enforcement. These developments are critical for in-house counsel, regulatory affairs specialists, and law firms involved in opioid-related litigation and compliance management.
By the numbers:
- 641 million — opioid pills dispensed by Albertsons in Washington (2006-2022)
- 6.5 million — prescriptions with misuse or diversion indicators at Albertsons
- 6 — national pharmacy compliance staff at Albertsons (2015-2020)
- $774 million — Albertsons’ nationwide opioid settlement in April 2026
Yes, but: Albertsons claims it provided adequate tools and monitoring for pharmacists, but limited compliance staffing suggests potential gaps in oversight capacity.
What's next: The trial continues with more expert testimony expected to clarify operational compliance and its legal implications for pharmacy standards in Washington.